If, on rigorous analysis, a clinic does not return more than it costs and/or can’t demonstrate enhanced health outcomes, what’s the point?
This comprehensive review provides examples of drug pricing that will make you grind your teeth.
Benefits managers’ and CFOs’ rage simmers below the courtesy that modern business practice demands, but that anger foments searches for better solutions in every healthcare niche.
Published Online 6/27/2016 in JAMA Internal Medicine. A couple of months before Elaine died from peritoneal cancer, we hired Anila,
Physicians, like all of us, may have inherent biases that manifest in what treatments they urge for their patients.
Plans like Molina and Centene, grounded in long managed Medicaid experience, have of necessity learned to manage risk more effectively than commercial plans.
Companies that the data say are the very best within their niches are often outsiders to a health system that protects low value. Rewarding high performance and turning away from low performance is the one surefire way purchasers can change how US health care works.